McEwen Stem Cell Institute at the University Health Network (UHN) is a global leader in stem cell research and regenerative medicine

Vancouver, BC, Canada - November 30, 2021 - Aspect Biosystems, a biotechnology company pioneering the development of bioprinted cell therapies as medicines of the future, is pleased to announce a research agreement with the University Health Network (UHN). Through this collaboration, Aspect Biosystems will combine its bioprinting technology with UHN’s protocols for differentiating stem cells into hepatocytes with the goal of developing bioprinted cell therapies for multiple genetic and acquired liver diseases. The agreement provides Aspect Biosystems an option to commercialize the technology as well as the methods of differentiating stem cells into hepatocytes.

UHN is Canada’s largest research hospital and includes the McEwen Stem Cell Institute: a recognized leader in stem cell research and regenerative medicine with an aim to unleash the potential for stem cell therapies. UHN is fully affiliated with the University of Toronto.